Hoth Therapeutics enters new CEO employment agreement with $550k salary and 800k share grant

Hoth Therapeutics, Inc.

CEO Robb Knie's new employment agreement includes $550,000 annual base salary and up to $550,000 annual bonus.
800,000 shares of common stock granted to Knie, vesting fully on grant date August 27, 2025.
Agreement provides for transaction bonus tied to equity value if company engages in license, joint venture, or change of control.
Company filed PCT patent application for HT-001, a topical treatment for side effects of cancer drugs, claiming priority to two U.S. provisionals.

item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.